Aderans Research reached a major milestone in its hair
restoration studies recently when the company enrolled its 300th
subject in Phase 2 of its clinical trial. With a goal of at least
350 subjects, Aderans is well on its way to expanding industry
knowledge about cell-based engineering solutions for pattern hair
loss. We will continue to evaluate various combinations of the Ji
Gami cell family in clinical treatment regimens, said Chief
Executive Officer Ken Washenik, M.D., Ph.D. The results are very
encouraging thus far, and were on course to finish Phase 2 next
year, added Vern Liebmann, Chief Operating Officer. Launched in
November 2008, Phase 2 is being conducted across the United States
and is open to select individuals who suffer from androgenetic
alopecia. Aderans continues to recruit subjects; visit
http://www.aderansresearch.com/ari_clinicupdates.html for current
locations.
No comments:
Post a Comment